Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Healthcare Drug Manufacturers - Specialty & Generic
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more

Recent & Breaking News (NEO:CYBN)

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program

Business Wire December 6, 2023

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results

Business Wire December 5, 2023

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Business Wire November 30, 2023

Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

Business Wire November 20, 2023

Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023

Business Wire November 16, 2023

Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting

Business Wire November 15, 2023

Cybin Reports Second Quarter Financial Results and Recent Business Highlights

Business Wire November 14, 2023

Cybin Announces Closing of Offering of Units Led by One of the Company's Largest Institutional Shareholders

Business Wire November 14, 2023

Canadian Investment Regulatory Organization Trade Resumption - CYBN

Canada NewsWire November 10, 2023

Canadian Investment Regulatory Organization Trading Halt - CYBN

Canada NewsWire November 10, 2023

Cybin Announces up to US$64 Million Offering of Units

Business Wire November 10, 2023

Cybin to Participate at the 2023 Milken Institute Future of Health Summit

Business Wire November 3, 2023

Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023

Newsfile November 1, 2023

Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline

Business Wire November 1, 2023

Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023

PR Newswire October 31, 2023

Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Business Wire October 31, 2023

Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs

Business Wire October 26, 2023

Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program

Business Wire October 25, 2023

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

Business Wire October 23, 2023

Small Pharma Obtains Final Order Approving Arrangement

Business Wire October 17, 2023